Genmab A/s(FRA) GE9

Genmab A/S is a biotechnology company based in Copenhagen, Denmark, focused on developing innovative antibody therapeutics for cancer and other medical conditions. Established in 1999, Genmab has made significant strides in the biotechnology sector, offering several key therapies and maintaining a robust product pipeline.

Products and Services

• DARZALEX, a monoclonal antibody for multiple myeloma
• Teprotumumab for thyroid eye disease
• Amivantamab for advanced gastric and non-small cell lung cancer

Growth Outlook

• Recent quarterly revenue reached €1.13 billion, showcasing strong market demand
• Significant product pipeline with multiple therapies in late-stage development
• Strategic partnerships with leading firms enhance growth potential

Financial Highlights

• Net income for Q2 2026 was €297 million, reflecting strong operational performance
• TTM revenue of €4.2 billion indicates consistent growth trajectory
• Operating income margin improved to 35.2% in Q2 2026, demonstrating operational efficiency

Genmab A/S has established itself as a leader in the biotechnology industry, particularly in the development of antibody-based therapies. The company's flagship products, such as DARZALEX, have gained significant traction in the market, contributing to impressive revenue figures. The recent quarterly results highlight a robust financial performance, with a notable increase in net income and operating income margins. The growth outlook for Genmab appears promising, bolstered by a strong product pipeline and strategic collaborations with other industry leaders. These partnerships not only enhance the company's research capabilities but also expand its market reach. With a focus on innovative therapies and a commitment to addressing unmet medical needs, Genmab A/S is well-positioned for continued success in the biotechnology sector.